BVS – bioventus inc. - class a (US:NASDAQ)

News

Bioventus Inc. (NYSE: BVS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $7.00 to $8.00. They now have a "buy" rating on the stock.
Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Bioventus Reports First Quarter Financial Results [Yahoo! Finance]
Bioventus Reports First Quarter Financial Results
Osteoarthritis Market Forecast Reveals Significant Growth and Upcoming Therapeutic Advancements by 2032 [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com